

**EMBARGOED FOR RELEASE:** Wednesday, October 13, 2010, 3 p.m. EDT

**CONTACT:** Jerry Berger, (617) 667-7308; [jberger@bidmc.harvard.edu](mailto:jberger@bidmc.harvard.edu);

Dana Wormer, (215) 888-0960; [dana.wormer@genomequest.com](mailto:dana.wormer@genomequest.com)

**BETH ISRAEL DEACONESS MEDICAL CENTER AND GENOME QUEST  
COLLABORATE IN PERSONALIZED HEALTH CARE INITIATIVE**

BOSTON – GenomeQuest, Inc., a global leader in sequence data management, and Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard Medical School, today announced a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized health care. The announcement was made during the opening session of the World Health Forum, held at Harvard Medical School.

The agreement will initially provide BIDMC’s Department of Pathology with newly developed applications to enable doctors and patients to make use of predictive genomic information.

“The precise and careful application of clinical genomics is the ultimate in personalized health care,” explains BIDMC Chief of Pathology Jeffrey Saffitz, MD, PhD. “By partnering with Genome Quest, our Department of Pathology will be able to perform genomic analyses and to collaborate with industry partners, without a heavy investment in information technology. The end result will profoundly fine-tune and improve patient diagnosis, treatment, and outcomes.”

GenomeQuest will provide whole-genome data management and analysis capabilities for all “next-generation sequencing” projects in BIDMC’s Department of Pathology. GenomeQuest will also provide API access and training to the department’s scientific investigators and applied mathematicians. BIDMC pathologists will develop “clinical grade” annotation methods and databases for diagnoses of cancers and other diseases. Collaborative projects will span user interface, workflows, sequence and annotation management, and integration into health care IT systems.

“It’s been seven years since the completion of the human genome project,” notes Genome Quest Acting CEO Richard Resnick. “Now, the plummeting cost of sequencing and the increasing volume of predictive, public studies makes the clinical application of genomics not just a practicality but a health care imperative. Already, the U.S. Food and Drug Administration [FDA] has approved over 30 drugs with biomarker guidelines for treatment. We believe that our

collaboration with a combined innovation and delivery leader like BIDMC is a major step forward in expanding genomics and its rewards from the bench to the bedside.”

“The latest PriceWaterHouseCoopers report on personalized medicine estimates that this market will grow to nearly \$500 billion in 2015 and terms it a ‘disruptive innovation’ for life sciences,” adds Saffitz. “The BIDMC Pathology Department is already a national leader in the development and application of genomics for personalized medicine, having launched it [Genomic Medicine Training Initiative](#) one year ago, and, this past spring, issuing a ‘Call to Action’ for pathology training programs across North America to do the same. Our collaboration with GenomeQuest helps provide us with the infrastructure to continue this work.”

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks in the top four in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information visit [www.bidmc.org](http://www.bidmc.org).

GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. Over 160 leading health and agriculture companies use GenomeQuest for mission-critical work, including nine of the top ten pharmaceuticals. The core technology of the company is the GQ-Engine – a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale.